Umeclidinium
Other / unclassified targets CHRM3 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 4 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (2) | US (FDA) | INCRUSE ELLIPTA | — | 2016-02-24 – 2019-06-06 | fda.gov ↗ |
| Approved | EU (EMA) | Incruse Ellipta (previously Incruse) | — | 2014-04-28 | europa.eu ↗ |
| Approved | US (FDA) | ANORO ELLIPTA | — | 2013-12-18 | fda.gov ↗ |
Trials 83 · started per year
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 116 trials | ||||||
| Phase 1 | NCT02837380 | Sep → Nov 2016 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01934153 | Sep 2013 → Feb 2014 | — | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01894386 | Jul → Sep 2013 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01899638 | May → Jul 2013 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01691547 | Dec 2012 → Mar 2013 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01725685 | Nov 2012 → Jan 2013 | asthma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01571999 | Mar → Jun 2012 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01577680 | Mar → Jun 2012 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01521377 | Dec 2011 → Jun 2012 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01521390 | Oct → Dec 2011 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01362257 | Apr → Jun 2011 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01128634 | Mar → Apr 2010 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01013974 | Oct → Dec 2009 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00976144 | Jul → Sep 2009 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00803673 | May → Oct 2008 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00475436 | May → Sep 2007 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 213 trials | ||||||
| Phase 2 | NCT03645434 | Oct 2018 → Aug 2019 | chronic obstructive pulmonary disease | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT03002389 | Nov 2017 → Dec 2023 overdue | chronic obstructive pulmonary disease | University of Virginia | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03012061 | Jan 2017 → May 2018 | asthma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT02673619 | Mar → Dec 2016 | isolated hyperchlorhidrosis | Stiefel, a GSK Company | Completed | No outcome recorded |
| Phase 2 | NCT02563899 | Nov 2015 → Feb 2016 | isolated hyperchlorhidrosis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT02570165 | Nov 2015 → Jul 2016 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT02164539 | Jul 2014 → Jul 2015 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT01641692 | May 2012 → Feb 2013 | asthma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT01573624 | Apr 2012 → Feb 2013 | asthma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT01372410 | Jul → Oct 2011 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT01039675 | Jan → Apr 2010 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT01030965 | Dec 2009 → Jul 2010 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00732472 | Oct 2008 → Aug 2009 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 335 trials | ||||||
| Phase 3 | NCT05757102 | Apr 2023 → Jan 2027 expected | asthma | GlaxoSmithKline | Recruiting | No outcome recorded |
| Phase 3 | NCT04651777 | Aug 2022 → Aug 2023 overdue | asthma | Dr. Grace Parraga | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04937387 | Jul 2021 → Aug 2024 | asthma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT04536675 | Apr 2021 → Apr 2026 overdue | chronic obstructive pulmonary disease, non-small cell lung carcinoma | Samsung Medical Center | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03376932 | Jan 2019 → Feb 2021 | asthma | GlaxoSmithKline | Withdrawn | No outcome recorded |
| Phase 3 | NCT03184987 | Jun 2017 → Jun 2019 | asthma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT02924688 | Oct 2016 → Feb 2019 | asthma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT02731846 | Jun → Nov 2016 | chronic obstructive pulmonary disease | GlaxoSmithKline | Withdrawn | No outcome recorded |
| Phase 3 | NCT02184611 | May 2016 → Nov 2017 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT02487498 | Jul 2015 → Sep 2016 | chronic obstructive pulmonary disease | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT02345161 | Jan 2015 → Apr 2016 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT02257385 | Oct 2014 → May 2015 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01899742 | Sep 2014 → Jul 2015 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT02152605 | Sep 2014 → Mar 2015 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT02207829 | Sep 2014 → May 2015 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT02164513 | Jun 2014 → Jul 2017 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01957163 | Oct 2013 → Apr 2014 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT02119286 | Oct 2013 → Apr 2014 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01879410 | Jun 2013 → Jan 2014 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01822899 | Apr → Oct 2013 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01817764 | Mar → Oct 2013 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01777334 | Jan → Sep 2013 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01772147 | Jan → Aug 2013 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01702363 | Aug 2012 → Dec 2013 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01636713 | Jul 2012 → Oct 2013 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01491802 | Jan 2012 → Sep 2014 | chronic obstructive pulmonary disease | Queen's University | Completed | No outcome recorded |
| Phase 3 | NCT01376388 | Aug 2011 → Dec 2012 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01387230 | Jul 2011 → Feb 2012 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01323660 | Mar 2011 → Jul 2012 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01316900 | Mar 2011 → Apr 2012 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01313637 | Mar 2011 → Mar 2012 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01313650 | Mar 2011 → Apr 2012 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01328444 | Mar 2011 → Jun 2012 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01316913 | Mar 2011 → Apr 2012 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01316887 | Jan 2011 → Jul 2012 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 418 trials | ||||||
| Phase 4 | NCT07192016 | Mar 2026 → Sep 2027 expected | chronic obstructive pulmonary disease | Western University, Canada | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06372496 | Apr 2024 → Jul 2025 overdue | asthma | GlaxoSmithKline | Active not recruiting | No outcome recorded |
| Phase 4 | NCT06571942 | Nov 2023 → Jan 2025 overdue | chronic obstructive pulmonary disease | National Institute of Respiratory Diseases, Mexico | Recruiting | No outcome recorded |
| Phase 4 | NCT04923347 | Jun 2023 → Mar 2024 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT05535972 | Oct 2022 → Sep 2023 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT05292053 | Jul 2022 → Sep 2024 | chronic obstructive pulmonary disease | Baylor Research Institute | Completed | No outcome recorded |
| Phase 4 | NCT04522596 | May 2021 → Dec 2024 | chronic obstructive pulmonary disease, heart failure | Luis Puente Maestu | Unknown | No outcome recorded |
| Phase 4 | NCT03949842 | Jun 2019 → Nov 2022 | chronic obstructive pulmonary disease | GlaxoSmithKline | Withdrawn | No outcome recorded |
| Phase 4 | NCT03662711 | Nov 2018 → Oct 2022 | chronic obstructive pulmonary disease | Università degli Studi di Ferrara | Terminated | No outcome recorded |
| Phase 4 | NCT03478696 | Jun 2018 → Mar 2019 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT03478683 | Jun 2018 → Mar 2019 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT03467425 | Apr 2018 → Oct 2019 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT03474081 | Mar 2018 → Jul 2019 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT03034915 | Jun 2017 → Jun 2018 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT02799784 | Jul 2016 → Apr 2017 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT02275052 | Jan 2015 → Jun 2016 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT02257372 | Sep 2014 → Mar 2015 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT02236611 | Sep 2014 → Jun 2015 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07541378 | Mar 2024 → Feb 2025 | chronic obstructive pulmonary disease | Medical University of Bialystok | Suspended | No outcome recorded |
Also used as a comparator or background therapy in 13 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01110018 Comparator | Apr → Jun 2010 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03378648 Comparator | Dec 2017 → Apr 2019 | asthma, chronic obstructive pulmonary disease | Chiesi Farmaceutici S.p.A. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04072887 Background | Sep 2019 → Oct 2021 | chronic obstructive pulmonary disease | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00515502 Comparator | Jun → Nov 2007 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT03162055 Comparator | May 2017 → May 2018 | chronic obstructive pulmonary disease | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT02729051 Comparator | Jun 2016 → May 2017 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01772134 Comparator | Jan → Jul 2013 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 44 trials | ||||||
| Phase 4 | NCT06552364 Comparator | Apr 2025 → Dec 2026 expected | chronic obstructive pulmonary disease | University of British Columbia | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07133880 Comparator | Dec 2023 → Dec 2025 overdue | chronic obstructive pulmonary disease | University of Tennessee Graduate School of Medicine | Recruiting | No outcome recorded |
| Phase 4 | NCT03611699 Comparator | Jan 2019 → Apr 2020 | chronic obstructive pulmonary disease | Gary L. Pierce | Completed | No outcome recorded |
| Phase 4 | NCT05342558 Comparator | Sep 2017 → Nov 2020 | chronic obstructive pulmonary disease | National Institute of Respiratory Diseases, Mexico | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT07329946 Background | Sep 2026 → Feb 2027 expected | chronic obstructive pulmonary disease | Pierachille Santus, MD, PhD | Not yet recruiting | No outcome recorded |
| — | NCT07058259 Background | Nov 2024 → Jun 2025 overdue | chronic obstructive pulmonary disease | Istanbul Medeniyet University | Active not recruiting | No outcome recorded |
Evidence & citations 24 cited values
Every value below carries the sentence it was read from. 102 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Umeclidinium | “We present the protocol for the ongoing INTREPID (INvestigation of TRelegy Effectiveness: usual PractIce Design; ClinicalTrials.gov identifier: NCT03467425) study, a...” PMID 31720293 ↗ Nov 201958“Participants will inhale a ultra Long-Acting Beta-Agonist (LABA; vilanterol (25mcg)) + Long-acting Muscarinic Antagonist (LAMA; umeclidinium (62.5mcg)) combination medication...” NCT06552364 ↗ “Dual Therapy (LABA + LAMA): Patients receive a long-acting beta-agonist (LABA) such as Formoterol, Salmeterol, Olodaterol, Vilanterol, or Indacaterol, in combination with a...” NCT07058259 ↗ “Umeclidinium (UMEC; long-acting muscarinic antagonist [LAMA])/vilanterol (VI; long-acting beta2-agonist [LABA]) and fluticasone propionate/salmeterol (FP/SAL) (inhaled...” PMID 26006754 ↗ May 2015 “Effectiveness of Fluticasone Furoate/ Umeclidinium/ Vilanterol (FF/UMEC/VI) Using the Connected Inhaler System (CIS) as Compared With Fluticasone Proprionate/ Salmeterol...” NCT03376932 ↗ “pharmacokinetics of fluticasone furoate (FF), umeclidinium (UMEC), and vilanterol (VI) in patients with chronic obstructive pulmonary disease (COPD) when administered as a...” PMID 31321713 ↗ Jan 2020 “A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic...” NCT03474081 ↗ “A Study to Evaluate the Effect of the Combination of Umeclidinium (UMEC) and Vilanterol (VI) on Exercise Endurance Time (EET) in Participants With Chronic Obstructive Pulmonary...” NCT02275052 ↗ “Pharmacokinetics and tolerability of inhaled umeclidinium and vilanterol alone and in combination in healthy Chinese subjects: a randomized, open-label, crossover trial.” PMID 25816315 ↗ Mar 2015 “Comparative Efficacy of Once-Daily Umeclidinium/Vilanterol and Tiotropium/Olodaterol Therapy in Symptomatic Chronic Obstructive Pulmonary Disease: A Randomized Study.” PMID 29094315 ↗ Nov 2017 “A Phase IIIb Study to Evaluate the Efficacy of Umeclidinium/Vilanterol (UMEC/VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)” NCT02152605 ↗ “Umeclidinium bromide (UMEC) is an inhaled long-acting muscarinic antagonist in development for chronic obstructive pulmonary disease (COPD).” PMID 24393134 ↗ Jan 2014 “long-acting muscarinic antagonist/β2-agonist combination umeclidinium/vilanterol (UMEC/VI) compared with UMEC and VI monotherapies” PMID 23830094 ↗ Jul 2013 “A combination of fluticasone furoate (FF) and umeclidinium (UMEC) has been considered for development for the treatment of asthma.” PMID 25700806 ↗ Feb 2015 “Fluticasone Furoate (FF)/ Umeclidinium (UMEC)/ Vilanterol (VI) on lung function compared with FF/VI after 24 weeks of treatment.” NCT05757102 ↗ “Umeclidinium bromide in a powder blend with lactose and magnesium stearate was used at two different doses 62.5mcg and 125mcg.” NCT02119286 ↗ “the first strip contains umeclidinium bromide (62.5 mcg per blister) blended with lactose monohydrate and magnesium stearate” NCT03034915 ↗ “inhaler approved by FDA (strength umeclidinium 65 microgram + vilanterol 25 microgram) One puff once a day for 30 days” NCT03002389 ↗ “The effect of fluticasone furoate/umeclidinium in adult patients with asthma: a randomized, dose-ranging study.” PMID 25452139 ↗ Oct 2014 “TRELEGY ELLIPTA (fluticasone furoate 100 mcg, umeclidinium 62.5 mcg, and vilanterol 25 mcg inhalation powder)” NCT05292053 ↗ “Limited data assessing the efficacy of the LAMA umeclidinium (UMEC) added to ICS/LABA are available.” PMID 27334739 ↗ Jun 2016 “fixed-dose combination bronchodilator (umeclidinium/vilanterol (UMEC/VI); 62.5 µg/25 µg)” PMID 34503985 ↗ Apr 2022 “Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) With Multiple Inhaler Therapy” NCT03478696 ↗ “Once-daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled study.” PMID 24385182 ↗ May 2014 “Phase IIb Study of Umeclidinium (UMEC) Bromide Versus Placebo in Subjects With Asthma” NCT03012061 ↗ “first strip contains Umeclidinium bromide (unit dose strengths 62.5 mcg per blister)” NCT02257385 ↗ “Fluticasone Furoate /Umeclidinium Bromide/Vilanterol (100/62.5/25 Microgram [mcg])” NCT02837380 ↗ “Umeclidinium is an inhaled long-acting muscarinic antagonist (LAMA).” NCT01691547 ↗ “Fluticasone Furoate (FF)/Umeclidinium(UMEC)/Vilanterol (VI)” NCT04923347 ↗ “umeclidinium (GSK573719) / vilanterol (GW642444)” NCT01491802 ↗ “umeclidinium (UMEC) plus vilanterol (VI)” PMID 24835833 ↗ May 2014 “Umeclidinium (UMEC)” NCT01894386 ↗ “Umeclidinium” NCT03662711 ↗ |
| Known as | Anoro ellipta | ChEMBL registry synonym — accepted as the source's own label CHEMBL1187833 ↗ |
| Known as | Bromure d'umeclidinium | ChEMBL registry synonym — accepted as the source's own label CHEMBL1187833 ↗ |
| Known as | Bromuro de umeclidinio | ChEMBL registry synonym — accepted as the source's own label CHEMBL1187833 ↗ |
| Known as | FF/UMEC/VI | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04937387 ↗ |
| Known as | FF/UMEC/VI (100/31.25/25) mcg | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02924688 ↗ |
| Known as | Fluticasone Furoate/Umeclidinium/Vilanterol | “Efficacy and Safety of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) in Chinese Participants With Inadequately Controlled Asthma” NCT04937387 ↗1“Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy” NCT03478683 ↗ |
| Known as | GSK-573719A | ChEMBL registry synonym — accepted as the source's own label CHEMBL1187833 ↗ |
| Known as | GSK573719 | “GSK573719 (500mcg) Inhalation Powder and GW642444 (25mcg) Inhalation Powder administered once-daily via a novel dry powder inhaler (Novel DPI)” NCT01039675 ↗26“Umeclidinium (GSK573719) 1.85% will be supplied as a clear, colourless solution, free from visible particulates, for topical application.” NCT02673619 ↗ “Umeclidinium (GSK573719) 1.85% will be supplied as a clear, colorless solution, free from visible particulates, for topical application.” NCT02563899 ↗ “A Healthy Volunteer Study With Inhaled GSK573719 and Placebo” NCT00803673 ↗ “umeclidinium (GSK573719) / vilanterol (GW642444)” NCT01491802 ↗ “GSK573719 Inhalation Powder (125mcg and 62.5mcg)” NCT01328444 ↗ |
| Known as | Incruse ellipta | ChEMBL registry synonym — accepted as the source's own label CHEMBL1187833 ↗ |
| Known as | Incruse ellipta (previously incruse) | ChEMBL registry synonym — accepted as the source's own label CHEMBL1187833 ↗ |
| Known as | Rolufta ellipta (previously rolufta) | ChEMBL registry synonym — accepted as the source's own label CHEMBL1187833 ↗ |
| Known as | UMEC | “We present the protocol for the ongoing INTREPID (INvestigation of TRelegy Effectiveness: usual PractIce Design; ClinicalTrials.gov identifier: NCT03467425) study, a...” PMID 31720293 ↗ Nov 201928“pharmacokinetics of fluticasone furoate (FF), umeclidinium (UMEC), and vilanterol (VI) in patients with chronic obstructive pulmonary disease (COPD) when administered as a...” PMID 31321713 ↗ Jan 2020 “A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic...” NCT03474081 ↗ “A Study to Evaluate the Effect of the Combination of Umeclidinium (UMEC) and Vilanterol (VI) on Exercise Endurance Time (EET) in Participants With Chronic Obstructive Pulmonary...” NCT02275052 ↗ “Umeclidinium bromide (UMEC) 62.5 μg is a long-acting muscarinic antagonist (LAMA) that is administered once daily via inhalation for chronic obstructive pulmonary disease...” PMID 26782971 ↗ Feb 2016 “Inhaled umeclidinium (UMEC) and the combination of inhaled UMEC with vilanterol (UMEC/VI) are approved maintenance treatments for chronic obstructive pulmonary disease in the US and EU.” PMID 25816315 ↗ Mar 2015 “A 24 Week Efficacy Study of Inhaled Umeclidinium (UMEC) in Patients of Chronic Obstructive Pulmonary Disease (COPD) Using a Novel Dry Powder Inhaler (NDPI)” NCT02184611 ↗ “A Phase IIIb Study to Evaluate the Efficacy of Umeclidinium/Vilanterol (UMEC/VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)” NCT02152605 ↗ “Umeclidinium bromide (UMEC) is an inhaled long-acting muscarinic antagonist in development for chronic obstructive pulmonary disease (COPD).” PMID 24393134 ↗ Jan 2014 “The long-acting muscarinic antagonists umeclidinium (UMEC) and tiotropium (TIO) are approved once-daily maintenance therapies for COPD.” PMID 27103795 ↗ Apr 2016 “long-acting muscarinic antagonist/β2-agonist combination umeclidinium/vilanterol (UMEC/VI) compared with UMEC and VI monotherapies” PMID 23830094 ↗ Jul 2013 “A combination of fluticasone furoate (FF) and umeclidinium (UMEC) has been considered for development for the treatment of asthma.” PMID 25700806 ↗ Feb 2015 “Fluticasone Furoate (FF)/ Umeclidinium (UMEC)/ Vilanterol (VI) on lung function compared with FF/VI after 24 weeks of treatment.” NCT05757102 ↗ “once-daily umeclidinium bromide (UMEC) was compared with once-daily tiotropium (TIO) and once-daily glycopyrronium (GLY)” PMID 29773969 ↗ May 2018 “Umeclidinium (UMEC; long-acting muscarinic antagonist) plus vilanterol (VI; long-acting beta2 agonist [LABA])” PMID 26286141 ↗ Aug 2015 “Limited data assessing the efficacy of the LAMA umeclidinium (UMEC) added to ICS/LABA are available.” PMID 27334739 ↗ Jun 2016 “fixed-dose combination bronchodilator (umeclidinium/vilanterol (UMEC/VI); 62.5 µg/25 µg)” PMID 34503985 ↗ Apr 2022 “Phase IIb Study of Umeclidinium (UMEC) Bromide Versus Placebo in Subjects With Asthma” NCT03012061 ↗ “Umeclidinium (UMEC) is a potent pan-active long-acting muscarinic antagonist (LAMA).” NCT02673619 ↗ “fluticasone furoate(FF)/umeclidinium (UMEC)/vilanterol(VI) (100/62.5/25) mcg” NCT07192016 ↗ “fluticasone furoate/umeclidinium bromide/vilanterol [FF/UMEC/VI]” NCT03949842 ↗ “Umeclidinium (UMEC; long-acting muscarinic antagonist [LAMA])” PMID 26006754 ↗ May 2015 “Fluticasone Furoate (FF)/Umeclidinium (UMEC)/Vilanterol (VI)” NCT02731846 ↗ “Fluticasone Furoate (FF)/Umeclidinium(UMEC)/Vilanterol (VI)” NCT04923347 ↗ “umeclidinium/vilanterol (UMEC/VI) 62.5/25 mcg and placebo” NCT02570165 ↗ “the long-acting muscarinic antagonist umeclidinium (UMEC)” PMID 33598874 ↗ Feb 2021 “umeclidinium (UMEC) plus vilanterol (VI)” PMID 24835833 ↗ May 2014 “umeclidinium bromide (UMEC)” NCT02164513 ↗ “Umeclidinium (UMEC)” NCT01894386 ↗ |
| Known as | Umeclidinium brom | ChEMBL registry synonym — accepted as the source's own label CHEMBL1187833 ↗ |
| Known as | umeclidinium bromide | “A 12-week, Prospective, Open Label, Single Cohort Study to Evaluate the Real-world Effectiveness of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol in a Single Inhaler...” NCT05535972 ↗19“Umeclidinium bromide/vilanterol (umeclidinium bromide 62.5 mcg; vilanterol 25mcg inhalation powder; trade name Anoro Ellipta) is a combination long-acting bronchodilator that...” NCT03611699 ↗ “Umeclidinium bromide is available as combination of fluticasone furoate/umeclidinium bromide inhalation powder (fluticasone furoate: 100 mcg per blister, umeclidinium bromide:...” NCT02164539 ↗ “Umeclidinium bromide (UMEC) 62.5 μg is a long-acting muscarinic antagonist (LAMA) that is administered once daily via inhalation for chronic obstructive pulmonary disease...” PMID 26782971 ↗ Feb 2016 “Umeclidinium bromide, long-acting muscarinic antagonist (LAMA). Administered as 55 μg, 1 inhalation once daily via Ellipta inhaler for 28 days in combination with vilanterol.” NCT07541378 ↗ “Umeclidinium bromide (UMEC) is an inhaled long-acting muscarinic antagonist in development for chronic obstructive pulmonary disease (COPD).” PMID 24393134 ↗ Jan 2014 “Fixed Dose Combination Therapy Fluticasone Furoate/Umeclidinium Bromide/Vilanterol Trifenatate in Japanese Patients With Asthma” NCT03184987 ↗ “Umeclidinium bromide in a powder blend with lactose and magnesium stearate was used at two different doses 62.5mcg and 125mcg.” NCT02119286 ↗ “Umeclidinium bromide in a powder blend with lactose and magnesium stearate was used at two different doses 62.5mcg and 125mcg.” NCT01957163 ↗ “the first strip contains umeclidinium bromide (62.5 mcg per blister) blended with lactose monohydrate and magnesium stearate” NCT03034915 ↗ “Combination of fluticasone furoate, vilanterol and umeclidinium bromide” NCT04072887 ↗ “fluticasone furoate/umeclidinium bromide/vilanterol [FF/UMEC/VI]” NCT03949842 ↗ “once daily in case of umeclidinium bromide/vilanterol 55/22 mcg” NCT07329946 ↗ “once-daily umeclidinium bromide (UMEC)” PMID 29773969 ↗ May 2018 “Umeclidinium bromide 62.5mcg” NCT01772147 ↗ “Umeclidinium bromide 62.5mcg” NCT01772134 ↗ “Drug: Umeclidinium bromide” NCT02184611 ↗ |
| Known as | Umeclidinium bromide component of trelegy ellipta | ChEMBL registry synonym — accepted as the source's own label CHEMBL1187833 ↗ |
| Known as | Umeclidinium cation | ChEMBL registry synonym — accepted as the source's own label CHEMBL1187833 ↗ |
| Known as | Umeclidinium ion | ChEMBL registry synonym — accepted as the source's own label CHEMBL1187833 ↗ |
| Known as | Umeclinidium bromide | “GSK573719 (Umeclinidium bromide) 15.6 mcg once-daily” NCT01641692 ↗ |
| Known as | umedlidinium | “The investigational drug is a single Ellipta inhaler containing 200 ug fluticasone furoate, 62.5 ug umedlidinium and 25 ug vilanterol.” NCT04651777 ↗ |
| Action | Inhibit | “GSK573719 is a high-affinity specific muscarinic receptor (mAChR) antagonist” NCT00515502 ↗1“Muscarinic acetylcholine receptor M3 antagonist” CHEMBL1187833 ↗ |
| Modality | Other / unclassified | “long-acting muscarinic antagonist” NCT01491802 ↗ |
| Route | Inhaled | “when administered via inhalation” NCT00475436 ↗ |
| Target | CHRM3 | “Muscarinic acetylcholine receptor M3 antagonist” CHEMBL1187833 ↗ |